Opportunities
Search

This Notice of Funding Opportunity (NOFO) is for support of National Centers for Cryoelectron Tomography (CryoET) to provide nationwide access to advanced cryoET instrumentation and technical support, and to assist investigators in acquiring the skills needed to perform cryoET studies.

Buyer: VERIFICACIONES INDUSTRIALES DE ANDALUCÍA, S.A. | Notice type: pin-rtl | Contract: services | Deadline: 2027-01-26

Buyer: ENEA Operator Sp. z o.o. | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-01-26

Buyer: VERIFICACIONES INDUSTRIALES DE ANDALUCÍA, S.A. | Notice type: pin-rtl | Contract: services | Deadline: 2027-01-26

Buyer: [SCS] Dirección General de Recursos Económicos del Servicio Canario de la Salud | Notice type: cn-standard | Procedure: restricted | Contract: supplies | Deadline: 2027-01-26

The purpose of the Tribal Institutional Review Board Establishment and Enhancement (TIRBEE) award is to support federally recognized American Indian/Alaska Native (AI/AN) Tribes, Tribal colleges and universities, Tribal health programs, or Tribal organizations(collectively, eligible Tribal entities) to establish Institutional Review Boards (IRBs) or enhance the capacity of existing Tribal IRBs.

The Biomedical Research Environment and Sponsored Programs Administration Development (BRE-SPAD) Program aims to promote broad participation in the biomedical research ecosystem by supporting resource limited organizations to conduct research, enhance the research environment, and increase sponsored programs administration capacity.This program intends to support eligible, domestic organizations with limited research resources and few biomedical doctoral students.

This Notice of Funding Opportunity (NOFO) invites applications for Diabetes Research Centers (DRCs) that are designed to support and enhance the national research effort in diabetes, its complications, and related endocrine and metabolic diseases. The purpose of this Centers program is to bring together basic and clinical investigators to enhance communication, multidisciplinary collaboration, and effectiveness of ongoing research in Diabetes Research Center topic areas. By providing shared access to specialized technical resources (research cores) and supporting a Pilot and Feasibility Program (P&F), DRCs are intended to create an environment that provides the capability for accomplishments greater than those that would be possible by individual research project grant support alone. New Center programs that bring in diverse perspectives, propose unique scientific themes, or provide innovative resources are encouraged. Emphasis will be placed on Center programs that propose enhanced synergies with other NIDDK-funded programs as well as providing a rich mentoring environment for future diabetes researchers.

Buyer: Aufbau- und Entwicklungsgesellschaft Bad Neuenahr-Ahrweiler mbH | Notice type: cn-standard | Procedure: open | Contract: works | Deadline: 2027-01-27

Buyer: Communauté de communes Brioude Sud Auvergne | Notice type: cn-standard | Contract: services | Deadline: 2027-01-27

Awarded activities will facilitate the translation of novel recording and modulation technologies that can be used to treat and/or diagnose central nervous system (CNS) diseases and disorders and to better understand the human CNS, from proof of concept up to the stage of readiness for first in human (FIH) studies. Technologies may incorporate any signal modality (e.g., electrical, optical, magnetic, acoustic) or a combination thereof. Diverse team-based applications that integrate appropriate domains of expertise are encouraged.

The purpose of this Notice of Funding Opportunity (NOFO) is to encourage investigators to pursue translational activities and small clinical studies to advance the development of therapeutic, and diagnostic devices for disorders that affect the nervous or neuromuscular systems. Activities supported in this program include implementation of clinical prototype devices, non-clinical safety and efficacy testing, design verification and validation activities, obtaining an Investigational Device Exemption (IDE) for a Significant Risk (SR) study or Institutional Review Board (IRB) approval for a Non-Significant Risk (NSR) study, as well as a subsequent small clinical study. The clinical study is expected to provide information about the device function or final design that cannot be practically obtained through additional non-clinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. This NOFO is a milestone-driven cooperative agreement program and will involve participation of NIH program staff in negotiating the final project plan before award and monitoring of research progress.

Quantum Machine Learning

Buyer: Akcinė bendrovė Lietuvos oro uostai | Notice type: cn-standard | Procedure: restricted | Contract: services | Deadline: 2027-01-28

This Notice of Funding Opportunity (NOFO) is issued by the Food and Drug Administration (FDA), Center for Veterinary Medicine (CVM), and solicits Research Project (R01) grant applications from institutions or organizations that propose to develop or support the development of designated new animal drugs intended for minor uses in major species or for use in minor species (MUMS).  The FDA is authorized to provide grants to assist in defraying the costs of qualified safety and effectiveness testing that could be used to satisfy the requirements for FDA approval of MUMS-designated drugs. Only entities developing drugs for veterinary use or parties working as research partners with such entities are eligible for grants. The organization (or applicant) seeking approval of the new animal drug under investigation must have opened an Investigational New Animal Drug (INAD) file with FDA/CVM and must hold a minor use or minor species "designation" granted by FDA/CVM's Office of Minor Use and Minor Species Animal Drug Development (OMUMS) for that drug for a specified intended use, in accordance with the provisions of section 573 of the Food, Drug and Cosmetic Act (21 U.S.C. 360ccc-2) and 21 CFR part 516. FDA/CVM's Office of New Animal Drug Evaluation (ONADE) must have reviewed and concurred with the proposed study protocol before an applicant can submit a grant application.

Buyer: Gemeente Amsterdam | Notice type: cn-social | Procedure: open | Contract: services | Deadline: 2027-01-29

Buyer: Vilniaus miesto savivaldybės administracija | Notice type: cn-standard | Procedure: restricted | Contract: supplies | Deadline: 2027-01-29

Buyer: Vilniaus miesto savivaldybės administracija | Notice type: cn-standard | Procedure: restricted | Contract: supplies | Deadline: 2027-01-29

Buyer: CPAM DE L'ESSONNE | Notice type: cn-standard | Procedure: open | Contract: services | Deadline: 2027-01-31

Buyer: Exploateringskontoret | Notice type: cn-standard | Procedure: oth-mult | Contract: services | Deadline: 2027-01-31

Buyer: AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-01-31

Buyer: Techniker Krankenkasse | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-01-31

Buyer: AOK Sachsen - Anhalt | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-01-31

Buyer: AOK Sachsen - Anhalt | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-01-31

Buyer: AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-01-31